Pall Medical is pleased to announce that Pall-Aquasafe Disposable Point-of-Use Water Filters have received FDA 510(k) clearance as a Class ll Medical Device.  The sterilizing grade water filters may aid in infection control by retaining waterborne bacteria.  Pall-Aquasafe produces water suitable for washing and drinking, superficial wound cleansing, cleaning of equipment used in medical procedures and washing of surgeon's hands. 
“Pall Medical has a long history of working with healthcare professionals to design, validate, and produce a diverse range of filtration devices for critical contamination control.  Our products are a vital link in the chain of infection prevention and cost containment.   
Pall-Aquasafe Water Filters enable hospitals and other healthcare facilities to reduce risk from waterborne microorganisms by acting as a barrier to bacteria at the patient point-of-use.”  said Eric Garnier, Vice President/General Manager, Pall Medical. 
In-building plumbing systems offer large surface areas for biofilm formation, and are susceptible to microbial colonization and growth.  Guidance for managing building water systems, and in particular Legionella, is available in the ANSI/ASHRAE Standard 188-2015 and a helpful implementation toolkit from the US Centers for Disease Control and Prevention.  Both these documents recognize that healthcare facilities contain more susceptible populations than the general public with regard to developing legionellosis, especially with high-risk patient groups such as burn, cancer, solid organ or bone marrow transplant, kidney disease, diabetes, chronic lung disease and intensive care.
As a control measure, Pall-Aquasafe Water Filters are effective for the continuous protection of high-risk patient groups, and can also be used more broadly to provide protection during periods of construction, validation, or equipment failure, and for immediate control when monitored microbial conditions drift outside the acceptable range. 
“Water Management Teams recognize that one of the most likely exposure routes to waterborne pathogens such as Legionella pneumophilaPseudomonas aeruginosa, Non-tuberculous Mycobacteria, Stenotrophomonas maltophiliaAspergillus fumigatus or Fusarium spp. is at the points-of-use.  Pall-Aquasafe filters provide a barrier to these pathogens at this critical point in the water network.  The filters are easy to install, require no additional plumbing and are available with service programs for changeouts, making them a simple and effective long term prophylactic for high-risk units, and as an immediate countermeasure for spikes in microbial contamination.” said Vincent Guercio, Senior Director, Global Marketing, Pall Medical.
Pall-Aquasafe Water Filters are supplied sterile and integrity tested. The robust Supor® membranes within the filter cartridge are rated and validated at 0.2 micron to remove bacteria, protozoa, fungi and particles in the water supply. They are intended to be used within the healthcare environment such as hospitals, nursing homes, health care facilities or clinical settings where immune-compromised patients may be exposed to waterborne microorganisms originating from the water supply.  Products covered under 510(k) Reference Number K153434 include:

  • AQF4A - Pall-Aquasafe - Disposable Shower Head Filter (12 units per case)
  • AQ31F1SA - Pall-Aquasafe - Disposable Water Filter - Faucet (with smooth outlet)
    (12 units per case)
  • AQ31F1RA - Pall-Aquasafe - Disposable Water Filter - Faucet (with shower rose outlet) (12 units per case)
  • AQINA - Pall-Aquasafe - ln-Line Disposable Water Filter (12 units per case)

Additional resources regarding these products and general in-premise water hygiene information is below.  If you have any questions please contact us for further support.

About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information, please visit, or follow us on social media at LinkedInTwitter; and YouTube.
Commercial Contact:                                                 Marketing Contact
Christopher Connolly                                                Vincent Guercio
Manager, Hospital Water Americas                          Senior Director, Strategic Marketing
Pall Medical                                                                Pall Medical
973.632.1920 mobile                                                 516.306.0947 mobile
Email:                               Email:


Additional resources

  • Photography and updated 510(k) sell sheet PDFs
  • ASHRAE 188 Legionellosis:  Risk Management for Building Water Systems. June 26 2015. ASHRAE, Atlanta.
  • Developing a Water Management Program to Reduce Legionella Growth & Spread in Buildings:  A Practical Guide to Implementing Industry Standard.  June 6 2016.  Centers for Disease Control & Prevention.
  • Legionella and the Prevention of Legionellosis.  World Health Organization 2007 ISBN 92 4 156297 8.
  • Water Safety in Buildings.  World Health Organization 2011 ISBN 978 924 154 810 6.
More Pall Corporation Press Releases
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
March 1, 2019 - Pall Corporation Obtains FAA PMA Approval and extends its Advanced Cabin Air Filters (A-CAF) product line to Boeing.
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing